daidzein, diadzein
| Name | Daidzein | ||
| PubChem CID | 5281708 | ||
| Molecular Weight | 254.24g/mol | ||
| Synonyms |
daidzein, diadzein |
||
| Formula | C₁₅H₁₀O₄ | ||
| SMILES | C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O | ||
| InChI | 1S/C15H10O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-8,16-17H | ||
| InChIKey | ZQSIJRDFPHDXIC-UHFFFAOYSA-N | ||
| CAS Number | 486-66-8 | ||
| ChEMBL ID | CHEMBL8145 | ||
| ChEBI ID | CHEBI:28197 | ||
| Herb ID | HBIN022577 | ||
| Drug Bank ID | DB13182 | ||
| KEGG ID | C10208 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | ChaiHu | ||
| Use Part | Root | ||
| Habitat | HuBei, SiChuan, AnHui | ||
| Flavor | Pungent, Bitter | ||
| Meridian Tropism | Liver, Gallbladder, Lung | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Apiaceae
-->Genus: Bupleurum
-->Species: Bupleurum scorzonerifolium
|
||
| Chineses Pinyin | DaDou | ||
| Habitat | China | ||
| Flavor | Pungent; Bitter | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Fabales
-->Family: Fabaceae
-->Genus: Glycin
-->Species: Glycine max
|
||
| Pair Name | Daidzein, Gefitinib | |||
| Partner Name | Gefitinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | AKT1 | hsa207 |
| Down-regulation | Expression | EGFR | hsa1956 | |
| Up-regulation | Activity | JUN | hsa3725 | |
| Up-regulation | Activity | MAP3K5 | hsa4217 | |
| Down-regulation | Expression | MAPK1 | hsa5594 | |
| Up-regulation | Activity | MAPK8 | hsa5599 | |
| Up-regulation | Activity | ROS1 | hsa6098 | |
| Down-regulation | Expression | SOAT1 | hsa6646 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | 4×10⁶ A549 cancer cells in Matrigel serum free medium (BD Biosciences) suspension were subcutaneously injected into 8-week-old male NU/NU mice hind legs. | |||
| Result | Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity | |||
| Pair Name | Daidzein, Topotecan | |||
| Partner Name | Topotecan | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Down-regulation | Expression | ABCG2 | hsa9429 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| In Vivo Model | Adult female athymic nude mice (six-week-old) were injected with MCF7 cells (5×10⁶ cells/mouse) to construct subcutaneous breast cancer xenografts. | |||
| Result | Daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. | |||
| Pair Name | Daidzein, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | MMP9 | hsa4318 |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| Result | This in vitro synergistic effect was mediated by suppression of MMP-9 and not by oxidative stress or Cas3-activated apoptosis. This study provides the basis for an in vivo and clinical trial of DZ-NS with concurrent chemotherapy. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Daidzein Synergizes with Gefitinib to Induce ROS/JNK/c-Jun Activation and Inhibit EGFR-STAT/AKT/ERK Pathways to enhance Lung Adenocarcinoma cells chemosensitivity. Int J Biol Sci. 2022 May 16;18(9):3636-3652. doi: 10.7150/ijbs.71870. | Click |
| 2 | Functional daidzein enhances the anticancer effect of topotecan and reverses BCRP-mediated drug resistance in breast cancer. Pharmacol Res. 2019 Sep;147:104387. doi: 10.1016/j.phrs.2019.104387. | Click |
| 3 | Daidzein nanosuspension in combination with cisplatin to enhance therapeutic efficacy against A549 non-small lung cancer cells: an in vitro evaluation. Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec 30. doi: 10.1007/s00210-023-02924-5. | Click |
